Topiramate in patients with juvenile myoclonic epilepsy

Archives of Neurology

Volumn 62, Issue 11, 2005, Pages 1705-1708

  Biton, Victor ^a   Bourgeois, Blaise F D ^b  

^a Arkansas Epilepsy Program   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE;

ADD ON THERAPY; ADULT; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EPISTAXIS; EVALUATION; FEMALE; FLU LIKE SYNDROME; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HUMAN; INSOMNIA; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; MYOCLONUS EPILEPSY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL IMPAIRMENT;

ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSE; HUMANS; MALE; MYOCLONIC EPILEPSY, JUVENILE; TREATMENT OUTCOME;

EID: 27744582895     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.11.1705     Document Type: Article

References (22)

1. Montalenti E, Imperiale D, Rovera A, Bergamasco B, Benna P. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci. 2001;184:65-70.
2. Grünewald RA, Panayiotopoulos CP. Juvenile myoclonic epilepsy: a review. Arch Neurol. 1993;50:594-598.
3. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39:5-17.
4. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 1996;46:1684-1690.
5. Guberman A, Neto W, Gassmann-Mayer C; EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand. 2002;106:183-189.
6. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu S-C, Pledger G; Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology. 1999;52:1338-1344.
7. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology. 1999;52:1330-1337.
8. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G; Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology. 1999;52:1882-1887.
9. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S; EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107:165-175.
10. Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia. 1997;38(Suppl 1):S28-S30.
11. Sundqvist A, Tomson T, Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit. 1998;20:149-157.
12. Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol. 2003;60:1100-1105.
13. Kellett MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry. 1999;66:759-763.
14. Stephen LJ. Lamotrigine and topiramate may be a useful combination. Lancet. 1998;351:958-959.
15. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalized epilepsies. J Neurol Neurosurg Psychiatry. 2004;75:75-79.
16. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology. 2000;55:1106-1109.
17. Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia. 2004;45:1282-1286.
18. Gram L, Wulff K, Rasmussen KE, et al. Valproate sodium: a controlled clinical trial including monitoring of drug levels. Epilepsia. 1977;18:141-148.
19. Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential? CNS Drugs. 2003;17:633-640.
20. Lerman-Sagie T, Watemberg N, Kramer U, Shahar E, Lerman P. Absence seizures aggravated by valproic acid. Epilepsia. 2001;42:941-943.
21. Dodson WE, Kamin M, Kraut L, Olson WH, Wu S-C. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother. 2003;37:615-620.
22. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia. 2000;41:977-980.